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 6.1 Introduction
Schizophrenia (SZ) is a debilitating mental disorder associated with psychotic symptoms, 
such as hallucinations and delusions which affect nearly 0.8% of the population (Saha et al., 
2005). Disturbances of auditory perception are among the most characteristic features of SZ. 
Interview measures of perceptual abnormalities, as distinct from hallucinations, indicate that 
auditory distortions are more frequent than distortions in any other sensory modality, 
occurring in 42% of patients with SZ compared to 17% of healthy adults (Bunney et al., 
1999). Consistent with these subjective reports, behavioral measures of auditory processing 
have demonstrated deficits in time estimation (Carroll et al., 2009), spatial localization 
(Perrin et al., 2010), sound intensity discrimination (Bach et al., 2011) pitch discrimination 
(Leitman et al., 2008) and echoic memory (Strous et al., 1995). Event-related potential 
(ERP) findings suggest that auditory processing is affected within 50–200 ms of stimulus 
onset, including reduction of the P50 response to the first click of a paired click paradigm, 
impaired P50 gating, reduction of the auditory N100 component, and reduced mismatch 
negativity (see Hirayasu et al., 1998; Turetsky et al., 2007). Auditory hallucinations are a 
diagnostic criterion for SZ, and patients with auditory hallucinations show altered brain 
activation in left superior temporal gyrus and middle temporal gyrus compared to non-
hallucinating individuals (Kuhn and Gallinat, 2010). Consequently, the auditory system can 
provide a window into one of the key neurobehavioral symptoms.
The neural mechanisms which produce symptoms of SZ remain poorly understood, but 
accumulating evidence suggests that disturbances in neural synchrony and oscillatory 
activity may contribute to failures of effective connectivity and neural integration in the 
illness (Uhlhaas and Singer, 2010; Whittington, 2008; Basar, 2011). While noninvasive 
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measures currently cannot detect cellular signaling at the level of individual neurons and 
circuits in humans, the electroencephalogram (EEG) and magnetoencephalogram (MEG) 
can detect the synchronous activity of ensembles of neurons. Moreover, since both EEG and 
MEG are primarily generated by postsynaptic potentials, they are often highly sensitive to 
alterations in neurotransmission secondary to brain dysfunction or pharmacological 
manipulations (Luck et al., 2011). Thus, these measures have the potential to serve as 
biomarkers for disturbance of synchrony and oscillations in SZ.
 6.1.1. Auditory steady-state responses
The auditory steady-state response (ASSR) is a type of ERP which can test the integrity of 
auditory pathways and the capacity of these pathways to generate synchronous activity at 
specific frequencies (Brenner et al., 2009). ASSRs are elicited by temporally modulated 
auditory stimulation, such as a train of clicks with a fixed inter-click interval, or an 
amplitude modulated (AM) tone. After the onset of the stimulus, the EEG or MEG rapidly 
entrains to the frequency and phase of the stimulus. Testing the capacity of auditory circuits 
to support entrainment provides a noninvasive method to determine the relationship of the 
power or phase of the output (EEG) to the characteristics of the periodic input. If the 
auditory system is unable to support neural synchronization, particularly at higher gamma 
frequencies (> 30 Hz), this would be evident in the amplitude or phase variability of the 
ASSR.
The ASSR is generated by activity within the auditory pathway. The ASSR for modulation 
frequencies up to 50 Hz is generated from the auditory cortex based on EEG (Pantev et al., 
1996; Herdman et al., 2002), MEG (Ross et al., 2002) and animal studies (Dolphin and 
Mountain, 1992; Conti et al., 1999). Higher frequencies of modulation (> 80 Hz) are thought 
to originate from brainstem areas (Herdman et al., 2002). The type of stimulus may also 
affect the region of activation within the auditory cortex. Amplitude modulated (AM) tones 
and click train stimuli are commonly used stimuli to evoke the ASSR (Picton et al., 2003). 
AM tones are generated by temporally modulating a tone (or sine wave) using another sine 
wave modulation resulting in variation of the amplitude of the tone over time. The frequency 
of the tone is referred to as the carrier frequency and the frequency of the modulation 
envelope is called the modulation frequency. The click train stimuli, on the other hand, 
consist of clicks which are brief but broad spectrum sound stimuli. Thus, the click stimulus 
has several harmonics, while the modulation frequency of AM tones has only one peak at 
the stimulus frequency. Due to tonotopic mapping of the auditory cortex, the carrier 
frequency or the frequency content in individual stimuli determines the region of the 
auditory cortex that is activated. In the case of the AM tones, only a small region that 
responds to the carrier frequency responds, while click stimuli activate a larger area. This is 
reflected in the amplitude of the ASSR responses, as clicks generate higher amplitude ASSR 
than AM tones. The mechanisms of generation of ASSRs differ as a function of frequency, 
but likely represent both the superposition of individual evoked potentials to each click or 
cycle of modulation, as well as intrinsic oscillatory processes in the auditory pathways. For 
further discussion of this issue, see Krishnan et al. (2009).
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 6.1.2. Time-frequency analysis of ASSRs
Entrainment is apparent in the ASSR averaged in the time domain (Fig. 1A and B), but the 
frequency response can be more accurately quantified using time-frequency analysis. One 
approach is to apply a Fast Fourier Transform (FFT) to the period of stimulation, or to the 
ASSR averaged across stimulus periods to improve signal to noise by isolating phase locked 
activity (Fig. 1C). The FFT decomposes the time domain ASSR into a sum of sinusoidal 
waveforms varying in power and phase. A power spectrum displays the coefficients for each 
frequency measured by the FFT as a graph of power values (usually in microvolts2), as 
shown in Fig. 1C. In Fig. 1, the ASSR was elicited by a 40 Hz amplitude modulated tone (1 
s duration) with a 1000 Hz carrier frequency. The power spectrum in Fig. 1C shows a 
prominent peak in power at 40 Hz, which has a larger value in the control group compared 
to the group of patients with SZ. The ASSR in humans shows a peak response at about 40–
45 Hz (Fig. 2).
More recently, signal analysis procedures have allowed trial-to-trial differentiation of phase 
consistency of the ASSR, and change in power from baseline. The phase locking factor 
(PLF), or inter-trial phase coherence, is a measure of phase synchronization of EEG activity 
across trials at particular temporal intervals and frequencies (Delorme and Makeig, 2004). In 
order to compute PLF, a baseline normalized spectrogram is first obtained by applying FFT 
using a time sliding window on single trial data. This results in a time-frequency transform 
consisting of a complex number for every time point, frequency and trial. This complex 
output is divided by its complex norm (absolute value), which is then averaged across trials. 
The complex norm of this averaged value results in PLF for different time and frequency 
points. PLF values can range from 0 (absence of synchronization) to 1 (perfect 
synchronization, or phase reproducibility across trials at a given latency). In contrast, mean 
power (MP) difference from baseline (also called event-related spectral perturbation (ERSP) 
measures the power in a frequency band relative to baseline. MP is obtained by first 
subtracting the power from the prestimulus baseline period and then averaging across trials. 
This measure represents the average change in power at a given frequency from the mean 
baseline power and so can detect changes in power that are induced by, but are not 
necessarily phase-locked to, stimulus onset. Fig. 1D and E show time-frequency plots 
comparing MP (or ERSP) and PLF (inter-trial coherence) for subjects with and without SZ 
to the 40 Hz AM tone.
 6.1.3. ASSRs in schizophrenia
ASSRs are usually reduced in power or phase locking in patients with schizophrenia to 40 
Hz stimulation (Table 1). Kwon et al. (1999) first reported that SZ patients showed a 
reduction in the ASSR. Short, 500 ms click trains were used to elicit the ASSR at three 
frequencies: 20, 30 and 40 Hz. Patients with schizophrenia showed a reduction in power at 
40 Hz, but not at 20 or 30 Hz. Moreover, patients showed delayed onset of phase 
synchronization and delayed desynchronization to the 40 Hz click trains. Subsequently, a 
reduction in 40 Hz power or PLF in SZ has been observed in most (Light et al., 2006; 
Vierling-Classen et al., 2008; Wilson et al., 2008; Spencer et al., 2009; Mulert et al., 2011) 
but not all (Hong et al., 2004) studies. Thirty and 40 Hz PLF ASSR reductions have been 
observed in first episode SZ (Spencer et al., 2008) and in adolescents with a diagnosis of a 
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psychotic disorder (Wilson et al., 2008) indicating that the deficit is probably not due to 
chronic illness or long-term medication effects. Type of stimulus may affect the specificity 
of the deficit to gamma range (> 30 Hz) frequencies. Studies which used AM tones rather 
than clicks to elicit the ASSR have found that power was reduced from 11 to 82 Hz (Brenner 
et al., 2003), and both power and PLF were reduced from 5 to 50 Hz (Krishnan et al., 2009). 
Hamm et al. (2011) used broad-band noise bursts and found that 5, 40 and 80 Hz ASSRs 
were attenuated in SZ, while 20 Hz was unaffected. Similar to findings by Hamm et al. 
(2011), unpublished data from the Krishnan et al. (2009) study also revealed an 80 Hz ASSR 
deficit in SZ. There is also evidence that the ASSR 40 Hz deficit is associated with genetic 
risk, although not with schizotypal personality characteristics. In the only study to examine 
first-degree relatives of SZ patients, Hong et al. (2004) reported that relatives showed a 
reduction in 40 Hz power. In contrast, individuals with schizotypal personality disorder, a 
phenotype which shares symptoms with schizophrenia, did not show a deficit in power at 42 
Hz or at any other frequency between between 11 and 82 Hz (Brenner et al, 2003).
ASSR deficits in 30–40 Hz range are suggestive of auditory cortex disturbances. Auditory 
cortex involvement in SZ has also been indicated by both imaging and neuropathological 
findings. Reduction of the grey matter volume of the posterior superior temporal gyrus, 
including auditory cortex, is a consistent neuroanatomical finding in SZ (Shenton et al., 
2001). At the cellular level, Sweet et al. (2003) have reported reduction of the volume of 
pyramidal neurons in the deep layer of primary and secondary auditory cortex in 
postmortem tissue from patients with SZ.
 6.1.4 Summary
Patients with SZ have typically demonstrated a deficit in ASSR power or PLF, which is most 
consistent at 40 Hz. This deficit is apparent for both EEG and MEG ASSR measures and is 
present at the first psychotic episode. The disturbance in synchrony affects a broader range 
of frequencies when AM tones, rather than clicks, are used as stimuli. Since the auditory 
cortex is the primary generator for scalp recorded ASSRs in the 40 Hz–50 Hz frequency 
range, these electrophysiological findings are convergent with other imaging data, 
demonstrating abnormalities in auditory cortex anatomy and function. The 40 Hz deficit also 
appears in first-degree relatives, suggesting that it may reflect genetic risk or shared 
environmental factors, but not in individuals with schizotypal personality disorder.
 6.2. Cellular mechanisms, pharmacology and animal models
ASSRs demonstrate alterations in a key system affected by SZ, the auditory pathways and 
auditory cortex. The interpretation of this deficit and its value as a biomarker depend in part 
on understanding the cellular mechanisms responsible for synchrony and oscillatory activity 
within neural networks, and how these are disturbed by putative pathophysiological 
processes. Consequently, in vitro and in vivo studies of neurobiological mechanisms in 
animal models will likely play a critical role in further understanding cellular mechanism 
and evaluating novel treatments in both preclinical and clinical stages of development. 
Gamma range oscillatory activity (30–80 Hz) has been widely studied across a range of 
mammalian species (Ehrlichman et al., 2009; Lazarewicz et al., 2010).
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 6.2.1. Generation of gamma oscillations
Neural oscillations are a putative mechanism for sensory, attentional, mnemonic and motoric 
processes (Singer, 1999; Basar, 2011. A number of models have been developed to identify 
important components and network properties associated with neural synchronization. Data 
from both in vitro and in vivo investigations support the role of synaptic inhibition in the 
generation of neuronal oscillations, either in an interneuronal network or in a reciprocal 
excitatory–inhibitory loop (Wang, 2010).
In vitro studies suggest that two major cell types, excitatory principal neurons and inhibitory 
interneurons, and two specific receptor types, gamma-aminobutyric acid (GABA) and N-
methyl-D-aspartate (NMDA), are critical for neural synchronization (Roopun et al., 2008) in 
the gamma frequency range. It was originally postulated that among interneuron networks, 
precise, in-phase firing modulates excitatory glutamatergic pyramidal neuron activity 
(Whittington et al., 1995; Gray and McCormick, 1996; Traub et al., 1996; Whittington, 
2008).
Once activated by glutamatergic (NMDA) receptors, GABAergic interneurons generate post-
synaptic interneuronal potentials (Traub et al., 1996) and engage in ongoing mutual 
inhibition and a recurrent feedback loop (Whittington et al., 1995). It has since been 
demonstrated that trains of fast, somatic inhibitory post-synaptic potentials mediated by the 
GABAA receptor are present in all forms of gamma oscillations (Roopun et al., 2008). High 
frequency synchronization is likely propagated through networks in a cycle of GABAA 
mediated inhibition followed by rebound excitation and then inhibition (Lewis and 
Gonzalez-Burgos, 2008). The NMDA receptor is thought to contribute to the generation of 
network oscillations via modulation of both interneuron to interneuron and interneuron to 
pyramidal neuron, cell connections. A recent in vitro study demonstrated that the effects of 
altering NMDA function via ketamine administration may be region specific. Roopun et al. 
(2008) used horizontal cortical slices to examine the effects of NMDA antagonism of beta2 
(20–29 Hz) and gamma (30–80 Hz) range oscillations. This study showed that, following the 
administration of ketamine, beta2 power increased in association with prelimbic cortices, 
while gamma range power was decreased in slice recordings of several regions (medial 
entorhinal, perirhinal, insular, and medial orbital cortices). Of the areas studied, NMDA-
induced increase in gamma power was only detected in auditory cortex. In an in vivo study 
involving rodents, Pinault (2008) showed that acute blockade of NMDA receptors (with 
ketamine and MK-801) increased gamma activity in a dose-dependent manner. It could, 
therefore, be speculated that blocking excitation of inhibitory interneurons decreased phasic 
inhibitory post-synaptic potentials onto pyramidal cells, resulting in a net excitatory effect 
on the neuronal network.
In summary, while NMDA antagonists cause an increase in in vitro gamma activity in 
several brain regions, the auditory cortex appears to show the opposite effect for acute 
blockade. In vivo studies have shown an increase in gamma activity after acute NMDA 
blockade. These variations in synchronization patterns may result from intrinsic differences 
in NMDA signaling in different regions, or interactions among regions that are evident in in 
vivo studies (Kuwada et al., 2002; Roopun et al., 2008).
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 6.2.2. Pharmacological effects on ASSRs
The anatomical and functional organization of auditory pathways in humans and other 
mammalian species is comparable, allowing for the use of animals such as rodents to study 
ASSR in cross-species studies of schizophrenia-related phenotypes. However, an important 
issue is whether a specific animal model demonstrates the same frequency response function 
as that observed in humans. For example, while the healthy human brain has an ASSR 
resonant frequency at 40 Hz (Kwon et al., 1999), rat ASSRs appear to be maximal at a bout 
50 Hz (Fig. 3; (Vohs et al., 2010). It has been argued that this difference should not preclude 
the use of rodents in ASSR studies because the observed frequency shift is likely secondary 
to brain volume differences (see Leiser et al., 2011 for further information).
Because NMDA and GABAergic interneurons are thought to be the most likely candidate 
mechanisms for ASSR generation, studies examining pharmacological effects on this 
response have focused on these transmitter systems. However, few studies have utilized 
pharmacological manipulation on ASSRs. NMDA receptor antagonism via phencyclidine 
(PCP), MK-801, or ketamine administration induces schizophrenic-like symptoms in healthy 
individuals (Javitt and Zukin, 1991; Krystal et al., 1994) and exacerbates psychoses in 
patients with schizophrenia (Lahti et al., 1995; Malhotra et al., 1997). These effects likely 
reflect dysregulation of the glutamatergic system, and more specifically the NMDA receptor, 
in the disorder (Tsai et al., 1998). NMDA receptor antagonism not only induces positive 
(similar to amphetamine psychosis), but also mimics negative and cognitive symptoms 
associated with schizophrenia. As in patients with schizophrenia and healthy subjects 
(Plourde et al., 1997), NMDA antagonism (ketamine MK-801 PCP) produces an increase in 
baseline (unevoked) gamma power in vivo local field potentials (LFPs) and EEG in awake 
rodents (Pinault, 2008; Ehrlichman et al., 2009; Hakami et al., 2009; Lazarewicz et al., 
2010). While these studies mostly examined baseline gamma magnitude and suggested that 
NMDA antagonism increased gamma, none specifically tested ASSRs. In humans, it has 
been demonstrated that ketamine increased the 40 Hz ASSR in healthy individuals (Plourde 
et al., 1997). Ehrlichman et al. (2009), however, examined both baseline and evoked gamma 
band responses. These investigators found that subanesthetic (20 mg/kg) doses of ketamine 
produced increased baseline, but not evoked gamma response. Interestingly, dopamine 
agonism (D-amphetamine) did not alter gamma band response, suggesting that dopamine 
may not play a direct role in the gamma deficits observed in patients with schizophrenia.
 6.2.2. ASSRs in rodent models of schizophrenia phenotypes
EEG synchronization has recently been studied in rodent models of schizophrenia (Pinault, 
2008; Ehrlichman et al., 2009; Lazarewicz et al., 2010). However, limited data have been 
obtained using the ASSR protocol commonly employed in patients with schizophrenia in 
animal models. One such study (Vohs et al., 2010) elicited 40 Hz ASSRs from neonatal 
ventral hippocampal lesion (NVHL) model rats, an established rat model of schizophrenia. 
In addition, a pharmacological manipulation targeting the GABAA receptor was also 
performed to further elucidate this receptor’s role in ASSR generation and its status in the 
NVHL model. The authors found that agonism of the GABAA receptor yielded a strong 
lesion by drug interaction, with ASSR magnitude and synchronization decreased in NVHL 
and increased in sham rats (Vohs et al., 2010). These data suggested an alteration in GABAA 
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receptor function in NVHL rats and altered inhibitory transmission in the neuronal networks 
responsible for ASSR generation in NVHL rats.
 6.2.4. Summary
A key question in the application of a translational biomarker is whether a comparable 
neural response can be obtained in human and in an animal model. The ASSR can be 
elicited from a wide range of species, although initial studies suggest the need for better 
characterization of the frequency response function to both click and AM tone stimuli in 
rodent models. in vitro studies suggest that gamma range oscillations in cortical circuits are 
entrained by GABAA neurons and are reduced by NMDA receptor antagonists. Importantly, 
the effect of NMDA antagonists on gamma activity may vary across cortical regions, and 
between in vitro and in vivo preparations. Thus, while the sensitivity of gamma range 
activity has been demonstrated by both types of preparation, study of local circuit activity 
and neural populations in vivo will be required to better characterize the basis of specific 
pharmacological effects. Several studies have examined ASSRs in rodent models of 
schizophrenia-related phenotypes and suggest that this approach may offer a flexible vehicle 
for cross-species studies of pathophysiological mechanisms and medication effects.
 6.3. Discussion
ASSRs, particularly in the gamma frequency range (> 30 Hz), are reduced in power and 
phase synchronization in schizophrenia. Because synchronized neural activity appears to be 
critical for a wide range of perceptual, cognitive and motoric processes, oscillatory deficits 
may index a key mechanism for functional disconnection or integration in SZ (Basar et al., 
2001; Whittington, 2008; Uhlhaas and Singer, 2010). ASSRs therefore appear to have the 
potential to serve as a translational, cross-species biomarker for schizophrenia and related 
disorders. However, the functional significance of the ASSR deficit and its implications 
regarding the pathophysiology of SZ must be better characterized for this response to be 
effectively utilized as an informative biomarker in studying etiological factors, mechanisms 
and intervention effects.
The ASSR represents only one of a variety of EEG and MEG paradigms which can capture 
disturbances of neural synchrony or oscillations in schizophrenia (Basar et al., 2001; 
Uhlhaas and Singer, 2010; Basar, 2011). Gamma activity, for example, may also be evoked 
by the onset of an auditory stimulus, or induced by working memory demands in patients 
with schizophrenia. Moreover, gamma activity deficits have been observed in other disorders 
as well, including attention deficit hyperactivity disorder and bipolar disorder (see Basar and 
Guntekin, 2008, for review), and therefore are not specific to schizophrenia. Given the 
dependence on gamma oscillations on interactions among GABAergic and glutamatergic 
neurons within cortical circuits, it is not surprising that oscillatory deficits would be 
sensitive to a range of neuropsychiatric disorders.
From a clinical perspective, the relationship of ASSRs to the development and course of the 
illness, treatment, and outcomes is incompletely characterized. While it has been established 
the motoric, cognitive and social behavior deficits are often present in children who develop 
schizophrenia later in life (O’Donnell, 2007), there are no studies of ASSRs in high-risk or 
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prodromal individuals who later develop the illness. A single study (Hong et al., 2004) has 
reported that the 40 Hz ASSR deficit occurs in non-psychotic relatives of patients with 
schizophrenia, consistent with an effect of familial or genetic risk factors. No longitudinal 
studies have been conducted, and long- term test–retest reliability of the measure in SZ has 
not been evaluated. The relationship of ASSR deficits to long-term outcomes or treatment 
response has not been studied. Hong et al. (2004) reported that patients receiving novel 
antipsychotic medication may show enhanced 40 Hz activity, but no studies have examined 
ASSRs in patients before and after receiving antipsychotic medications.
The ease of recording ASSRs in animal models of SZ phenotypes suggests that these 
measures could also be highly informative in testing neurophysiological models of the 
disorder, particularly with respect to glutamate and GABAergic interactions. ASSRs can test 
cellular mechanisms that are not accessible through non-invasive measures in humans and 
could provide a preclinical measure to test novel antipsychotic treatments. The potential of a 
combined human and animal model approach to treatment development is especially 
intriguing and merits exploration in future research.
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Fig. 1. 
Auditory steady-state responses (ASSRs) to a 1-s, 40-Hz amplitude-modulated tone 
recorded at Cz in a healthy control group (HC; N = 21) and in patients with schizophrenia 
(SZ; N = 21). (A) The ERP in the time domain averaged across subjects, showing both a 
large onset response as well as the 40-Hz oscillation. In (B), the averaged wave form has 
been filtered between 39 and 41 Hz. (C) A power spectrum obtained by applying a Fast 
Fourier Transform on the ERPs in the two groups, showing the 40-Hz response in the HC 
group which is reduced in magnitude in the SZ group. (D) Mean power (MP) across the 
epoch which indicates the average change in power at a given frequency from the mean 
baseline power. The x-axis represents time in milliseconds, the y-axis represents frequency 
in Hertz, and the colors represent the magnitude of power. (E) The phase-locking factor 
(PLF) across trials. The x-axis indicates time in milliseconds, they-axis indicates frequency, 
and the colors represent phase reproducibility across trials ranging from 0 (absence of 
synchronization) to 1 (perfect synchronization). (For color figures, please refer to the color 
figures in last section of the book.)
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Fig. 2. 
The modulation transfer function (MTF) for the ASSR recorded at Cz from healthy control 
(HC; N = 21) and schizophrenia (SZ; N = 21) groups. The MTFs for the each stimulus 
frequency are displayed. Each data point is the mean value across the entire stimulus period 
averaged across subjects within the group. The error bars indicate standard errors. Note the 
large decrement in schizophrenia for both PLF and MP between 35 and 50 Hz.
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Fig. 3. 
Modulation transfer function of phase locking factor (PLF, left panel) and mean power (MP, 
right panel) to 10-s click trains in eight male rats, with frequency of stimulation on the x-
axis. The peak frequency of response for hoth phase locking and mean power is at a slightly 
higher frequency in rats than in humans (hetween 45 and 50 Hz).
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Table 1
Studies of Auditory Steady State Responses (ASSRs) in Schizophrenia and Related Disorders)
Author Stimuli Frequency Stimuli Type Group Results (Power, MP or PLF)
Kwon et al., 1999 20, 30, 40 Hz Clicks SZ Reduced 40 Hz
Brenner et al., 2003 11, 22, 31, 42,
51, 62, 82 Hz
AM Tones SZ Reduced across multiple
frequencies
Brenner et al., 2003 11, 22, 31, 42
51, 62, 82 Hz
AM Tones SPD No reduction at any frequency
Hong et al., 2004 20, 30, 40 Hz Clicks SZ No reduction at 40 Hz
Hong et al., 2004 20, 30, 40 Hz Clicks First-degree relatives Reduced 40 Hz
Light et al., 2006 20, 30, 40 Hz Clicks SZ Reduced 40 Hz
Spencer et al., 2008 20, 30, 40 Hz Clicks First-episode Psychosis: SZ Reduced 30, 40 Hz, reduced PLF
of 40 Hz harmonic of 20 HZ ASSR
Teale et al., 2008 40 Hz AM Tones SZ Reduced 40 Hz
Vierling-Classen et al., 
2008
20, 30, 40 Hz Clicks SZ Reduced 40 Hz, but increased 20 Hz
Wilson et al., 2008 40 Hz Clicks adolescent psychosis: SZ, BP Reduced 40 Hz
Krishnan et al., 2009 5 to 50 Hz AM tones SZ Broadband reduction
Spencer et al., 2009 40 Hz Clicks SZ Reduced 40 Hz
Mulert et al, 2011 40 Hz Clicks SZ Reduced 40 Hz
Hamm et al., 2011 5, 20, 40, 80
160 Hz
Broadband Noise
Bursts
SZ Reduced 5 Hz and 80 Hz, reduced 40 
Hz
in right hemisphere
Abbreviations: Schizophrenia (SZ), schizotypal personality disorders (SPD), mean power (MP), phase locking factor (PLF)
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